MX2009003260A - Probioticos para el uso en la reduccion de la incidencia y duracion de la enfermedad. - Google Patents

Probioticos para el uso en la reduccion de la incidencia y duracion de la enfermedad.

Info

Publication number
MX2009003260A
MX2009003260A MX2009003260A MX2009003260A MX2009003260A MX 2009003260 A MX2009003260 A MX 2009003260A MX 2009003260 A MX2009003260 A MX 2009003260A MX 2009003260 A MX2009003260 A MX 2009003260A MX 2009003260 A MX2009003260 A MX 2009003260A
Authority
MX
Mexico
Prior art keywords
incidence
duration
probiotics
illness
reducing
Prior art date
Application number
MX2009003260A
Other languages
English (en)
Spanish (es)
Inventor
Gregory Leyer
Arthur Ouwehand
Original Assignee
Danisco
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39268947&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2009003260(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Danisco filed Critical Danisco
Publication of MX2009003260A publication Critical patent/MX2009003260A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Otolaryngology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Nutrition Science (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
MX2009003260A 2006-10-02 2007-09-14 Probioticos para el uso en la reduccion de la incidencia y duracion de la enfermedad. MX2009003260A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US84866206P 2006-10-02 2006-10-02
PCT/US2007/020033 WO2008042101A2 (en) 2006-10-02 2007-09-14 Probiotics for use in reducing the incidence and duration of illness

Publications (1)

Publication Number Publication Date
MX2009003260A true MX2009003260A (es) 2009-05-11

Family

ID=39268947

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009003260A MX2009003260A (es) 2006-10-02 2007-09-14 Probioticos para el uso en la reduccion de la incidencia y duracion de la enfermedad.

Country Status (13)

Country Link
US (5) US20100040579A1 (enExample)
EP (2) EP2839836B2 (enExample)
JP (3) JP5896589B2 (enExample)
KR (2) KR101474188B1 (enExample)
CN (1) CN101528244B (enExample)
AU (1) AU2007302715B2 (enExample)
BR (1) BRPI0719787A2 (enExample)
DK (2) DK2839836T4 (enExample)
ES (2) ES2547480T3 (enExample)
FI (1) FI2839836T4 (enExample)
MX (1) MX2009003260A (enExample)
PL (2) PL2839836T5 (enExample)
WO (1) WO2008042101A2 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101372561B1 (ko) 2009-12-02 2014-03-13 주식회사 케이엠더블유 디바이스 선택 구조
JP5885287B2 (ja) * 2010-09-02 2016-03-15 アサヒカルピスウェルネス株式会社 インフルエンザの予防および／または治療剤
US20130195917A1 (en) * 2010-10-15 2013-08-01 Dorte Eskesen Immunoadjuvant
EP2455093A1 (en) 2010-11-11 2012-05-23 Nestec S.A. Non-replicating probiotic bacteria and prevention or treatment of infections in children
EP2455092A1 (en) 2010-11-11 2012-05-23 Nestec S.A. Non-replicating probiotic micro-organisms protect against upper respiratory tract infections
CN105722515A (zh) 2013-11-15 2016-06-29 雀巢产品技术援助有限公司 用于预防或治疗有风险婴儿或幼儿的urt感染的组合物
CN104886255B (zh) * 2014-03-07 2018-11-27 内蒙古伊利实业集团股份有限公司 具有缓解咽喉部炎症功效的益生菌食品组合物及食品
CN114532538A (zh) 2015-03-05 2022-05-27 雀巢产品有限公司 用于预防或治疗婴儿或幼儿的耳炎或支气管炎的组合物
WO2020170981A1 (ja) 2019-02-21 2020-08-27 オリンパス株式会社 フローラ治療用処置具、内視鏡、フローラ治療法
EP4040984B1 (en) 2019-09-25 2026-02-18 Tall Goods, LLC Methods for producing probiotics fortified avian eggs and egg products and formulations thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4007A (en) * 1845-04-22 Improvement in separating tannin and coloring-matter in quercitron-bark
EP0951531B1 (en) * 1996-11-29 2007-02-28 Bio K + International Inc. Lactic ferment comprising a particular strain of lactobacillus acidophilus and use thereof
JP4212838B2 (ja) * 2002-06-26 2009-01-21 カルピス株式会社 抗アレルギー剤
EP1549151A1 (en) * 2002-10-11 2005-07-06 Wyeth Nutritional formulations containing synbiotic substances
CA2550106A1 (en) * 2003-12-17 2005-06-30 N.V. Nutricia Lactic acid producing bacteria and lung function
DE102004026706A1 (de) * 2004-05-28 2005-12-15 Merck Patent Gmbh Orale Darreichungsform enthaltend probiotische Bakterien
CA2470090A1 (fr) * 2004-06-18 2005-12-18 Bio-K Plus International Inc. Bacteries lactiques et leurs usages dans la prevention de diarrhee associee aux antibiotiques
US7862808B2 (en) † 2004-07-01 2011-01-04 Mead Johnson Nutrition Company Method for preventing or treating respiratory infections and acute otitis media in infants using Lactobacillus rhamnosus LGG and Bifidobacterium lactis Bb-12
ITMI20042189A1 (it) * 2004-11-16 2005-02-16 Anidral Srl Composizione a base di batteri probiotici e suo uso nella prevenzione e-o nel trattamento di patologie e-o infezioni respiratorie e nel miglioramento della funzionalita' intestinale
EP1858340B1 (en) * 2005-02-15 2010-07-14 Barry R. Goldin A food containing a probiotic and an isolated beta-glucan and methods of use thereof
US20070020249A1 (en) * 2005-04-29 2007-01-25 Downs Bernard W Compositions for prevention and treatement of symptoms of gastrointestinal distress
AU2006297896B2 (en) 2005-10-06 2011-12-08 Probi Ab Use of lactobacillus for treatment of autoimmune diseases

Also Published As

Publication number Publication date
KR20140002069A (ko) 2014-01-07
ES2547480T3 (es) 2015-10-06
DK2839836T4 (da) 2024-08-26
EP2068899A2 (en) 2009-06-17
JP2014058558A (ja) 2014-04-03
PL2839836T5 (pl) 2025-11-17
KR101485200B1 (ko) 2015-01-26
US20100040579A1 (en) 2010-02-18
US20180000875A1 (en) 2018-01-04
US20200316145A1 (en) 2020-10-08
EP2839836B1 (en) 2017-08-30
US20140356329A1 (en) 2014-12-04
CN101528244A (zh) 2009-09-09
BRPI0719787A2 (pt) 2014-11-25
CN101528244B (zh) 2012-01-11
JP2016128478A (ja) 2016-07-14
EP2068899B1 (en) 2015-07-01
DK2068899T3 (da) 2015-09-28
WO2008042101A2 (en) 2008-04-10
ES2650375T3 (es) 2018-01-18
PL2068899T3 (pl) 2015-12-31
PL2839836T3 (pl) 2018-02-28
KR101474188B1 (ko) 2014-12-17
EP2839836A1 (en) 2015-02-25
AU2007302715B2 (en) 2013-01-31
AU2007302715A1 (en) 2008-04-10
ES2650375T5 (en) 2025-02-03
JP5896589B2 (ja) 2016-03-30
WO2008042101A3 (en) 2009-04-09
KR20090063222A (ko) 2009-06-17
DK2839836T3 (en) 2017-12-04
EP2839836B2 (en) 2024-06-26
JP2010505824A (ja) 2010-02-25
US20230256037A1 (en) 2023-08-17
FI2839836T4 (fi) 2024-08-26

Similar Documents

Publication Publication Date Title
LTPA2018010I1 (lt) Žmogaus anti-IL-23 antikūnai, kompozicijos, metodai ir panaudojimai
WO2008086395A3 (en) Anti-il-13 antibody formulations and uses thereof
ECSP10010295A (es) Formulacion de anticuerpo
NO345046B1 (no) Oral doseringsform
DOP2010000304A (es) Composiciones y metodos de preparacion y uso de las mismas
DK1773361T3 (da) Sammensætning baseret på probiotiske bakterier og anvendelse deraf til forebyggelse og/eller behandling af respiratoriske sygdomme og/eller infektioner og til forbedring af en intestinale funktionalitet
CR8642A (es) Compuestos, composiciones farmaceuticas y metodos para su uso en el tratameinto de desordenes metabolicos
NO20073722L (no) Farmasoystiske sammensetniger omfattende bendamustin
BRPI0720124A2 (pt) Composições farmacêuticas e seus métodos de uso.
ECSP13012379A (es) Pirimidinas y triazinas condensadas y su uso
WO2008042101A3 (en) Probiotics for use in reducing the incidence and duration of illness
AR052238A1 (es) Formulacion de tabletas estables
BRPI0821732A2 (pt) Formulações de liberação controlada , forma de dosagem sólida, e, uso da formulação de liberação controlada
CL2011001977A1 (es) Compuestos derivados de triazolopiridina, inhibidores de proteinas cinasas activadas por mitogeno p38; composicion farmaceutica; y su uso para el tratamiento de neumonia eosinofilica cronica, asma, enfermedad pulmonar obstructiva cronica y sindrome de angustia respiratoria en adultos, entre otras enfermedades.
WO2009002423A3 (en) Polycyclic guanine derivatives and use thereof
IT1362675B (it) N-idrossiammidi -sostituiti con gruppi triciclici come inibitori dell'istone deacelitasi,loro preparazione ed impiego in formulazioni farmaceutiche
CL2006001266A1 (es) Formas solidas cristalinas i, ii, iii, iv y v de tigeciclina; procedimiento de preparacion de las formas cristalinas ii, iv y v; composicion farmaceutica que comprende las formas cristalinas; y su uso para tratar infecciones bacterianas.
CL2013001230A1 (es) Composicion a base de cereales en polvo que comprenden microorganismos probioticos no replicantes; y su uso para prevenir o tratar desordenes inflamatorios o trastornos con una defensa inmune comprometida en lactantes o niños pequeños.
BRPI0818121A2 (pt) diespiro 1,2,4-trioxolano e seus métodos de fabricação e utilização
NO20074780L (no) Heterocyklylamidsubstituerte imidazoler
CY1112121T1 (el) ΠΑΡΑΓΩΓΑ ΤΩΝ 1,2,3,4-ΤΕΤΡΑΫΔΡΟΠΥΡΡΟΛΟ-[1,2-α]-ΠΥΡΑΖΙΝ-6-ΚΑΡΒΟΞΑΜΙΔΙΩΝ ΚΑΙ ΤΩΝ 2,3,4,5-ΤΕΤΡΑΫΔΡΟΠΥΡΡΟΛΟ-(1,2-α)-ΔΙΑΖΕΠΙΝ-7-ΚΑΡΒΟΞΑΜΙΔΙΩΝ, Η ΠΑΡΑΣΚΕΥΗ ΤΟΥΣ ΚΑΙ Η ΕΦΑΡΜΟΓΗ ΤΟΥΣ ΣΕ ΘΕΡΑΠΕΥΤΙΚΗ ΑΓΩΓΗ
WO2007025146A3 (en) Balsalazide formulations and manufacture and use thereof
SV2006002384A (es) Pirazolo piridinas sustituidas, composiciones que las contienen, procedimiento de fabricacion y utilizacion
BRPI0418466B1 (pt) conjunto de assentos de aeronave e aeronave.
AR056749A1 (es) Formulaciones de dosificacion oral de ibuprofeno organolepticamente aceptables metodos para su preparacion y uso

Legal Events

Date Code Title Description
FG Grant or registration
HC Change of company name or juridical status